EA201790824A3 - Векторы для генной терапии и цитозиндезаминазы - Google Patents

Векторы для генной терапии и цитозиндезаминазы

Info

Publication number
EA201790824A3
EA201790824A3 EA201790824A EA201790824A EA201790824A3 EA 201790824 A3 EA201790824 A3 EA 201790824A3 EA 201790824 A EA201790824 A EA 201790824A EA 201790824 A EA201790824 A EA 201790824A EA 201790824 A3 EA201790824 A3 EA 201790824A3
Authority
EA
Eurasian Patent Office
Prior art keywords
cytozindesaminase
vectors
genetic therapy
modified
present
Prior art date
Application number
EA201790824A
Other languages
English (en)
Other versions
EA201790824A2 (ru
Inventor
Гарри Е. Грубер
Дуглас Джолли
Омар Перес
Кристофер Р. Логг
Original Assignee
Токаджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Токаджен Инк. filed Critical Токаджен Инк.
Publication of EA201790824A2 publication Critical patent/EA201790824A2/ru
Publication of EA201790824A3 publication Critical patent/EA201790824A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к модифицированным цитозиндезаминазам (CD). Настоящее изобретение дополнительно относится к клеткам и вектору, экспрессирующим или содержащим такие модифицированные CD, и способам использования таких модифицированных CD при лечении заболеваний или нарушений.
EA201790824A 2008-09-26 2009-09-26 Векторы для генной терапии и цитозиндезаминазы EA201790824A3 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10066608P 2008-09-26 2008-09-26
US12061808P 2008-12-08 2008-12-08
US18682309P 2009-06-13 2009-06-13

Publications (2)

Publication Number Publication Date
EA201790824A2 EA201790824A2 (ru) 2017-08-31
EA201790824A3 true EA201790824A3 (ru) 2017-12-29

Family

ID=42060421

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201170492A EA027693B1 (ru) 2008-09-26 2009-09-26 Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации
EA201790824A EA201790824A3 (ru) 2008-09-26 2009-09-26 Векторы для генной терапии и цитозиндезаминазы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201170492A EA027693B1 (ru) 2008-09-26 2009-09-26 Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации

Country Status (18)

Country Link
US (3) US8722867B2 (ru)
EP (4) EP2346995B1 (ru)
JP (6) JP5771147B2 (ru)
KR (3) KR101724162B1 (ru)
CN (4) CN102227501B (ru)
AU (1) AU2009303690B2 (ru)
BR (1) BRPI0919113A2 (ru)
CA (1) CA2738472A1 (ru)
CO (1) CO6362050A2 (ru)
DK (1) DK2346995T3 (ru)
EA (2) EA027693B1 (ru)
ES (2) ES2709481T3 (ru)
IL (3) IL211847A (ru)
MX (3) MX2011003039A (ru)
MY (1) MY156333A (ru)
NZ (1) NZ592070A (ru)
WO (2) WO2010045002A2 (ru)
ZA (1) ZA201102115B (ru)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940521D1 (de) 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
MX366570B (es) 2008-06-30 2019-07-12 Tocagen Inc Formulaciones de 5-fluorocitosina y usos de las mismas.
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
ES2709481T3 (es) * 2008-09-26 2019-04-16 Tocagen Inc Vectores recombinantes
EP3159415B1 (en) 2009-06-17 2019-03-13 Tocagen Inc. Producer cells for replication competent retroviral vectors
WO2011156273A1 (en) * 2010-06-06 2011-12-15 Mount Sinai School Of Medicine Recombinant rna viruses and uses thereof
ES2655500T3 (es) 2010-07-16 2018-02-20 Tocagen Inc. Detección de retrovirus
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
US20140178854A1 (en) 2010-10-31 2014-06-26 Tocagen Inc. Antisera assays for mlv related viruses in humans and other mammals
CN102807620B (zh) * 2011-06-02 2017-10-27 台北荣民总医院 治疗感染性与恶性疾病的标靶化学治疗药物的形成方法
KR101554678B1 (ko) * 2012-10-19 2015-09-21 영남대학교 산학협력단 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도
ES2786051T3 (es) 2012-10-25 2020-10-08 Tocagen Inc Vector retroviral con casete de mini-promotor
WO2014078533A1 (en) * 2012-11-15 2014-05-22 Esperance Pharmaceuticals, Inc. Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
US20160175388A1 (en) 2013-06-15 2016-06-23 Tocagen Inc. Immunosuppressive components associated with retroviral replicating vectors
EP3030659A4 (en) * 2013-08-05 2017-01-11 Tocagen Inc. Recombinant vector with optimized a-bulge
CN103966260A (zh) * 2014-03-07 2014-08-06 山东农业大学 一种基于J亚群禽白血病病毒pol基因保守序列的siRNA重组干扰载体及其制备方法和应用
CA2943640A1 (en) * 2014-03-26 2015-10-01 Tocagen Inc. A retroviral vector having immune-stimulating activity
SG10201808825XA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Defined composition gene modified t-cell products
WO2015168102A2 (en) * 2014-04-28 2015-11-05 Board Of Regents, The University Of Texas System Prolonged protein stabilization by resveratrol
CN104557602B (zh) * 2015-01-07 2016-08-17 华东师范大学 三环二萜衍生物及其制备方法、及其在制备抗肿瘤药物中的应用
CN108174604B (zh) 2015-08-07 2023-06-23 西雅图儿童医院（Dba西雅图儿童研究所） 用于实体瘤靶向的双特异性car t细胞
JP2018526007A (ja) * 2015-09-04 2018-09-13 トカジェン インコーポレーテッド ２ａペプチドを含む組換えベクター
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
WO2018101498A1 (ko) 2016-11-29 2018-06-07 충남대학교 산학협력단 유전자치료 벡터시스템 및 전구약물 유전자
CN107058314B (zh) * 2016-11-30 2020-09-04 暨南大学 一种启动子及其应用
JP7091357B2 (ja) 2016-12-12 2022-06-27 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
EP3645719B1 (en) 2017-06-30 2022-03-09 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
AU2018301701A1 (en) * 2017-07-14 2020-02-27 Elevatebio Technologies, Inc. Encapsulated polynucleotides and methods of use
US20200392512A1 (en) * 2018-02-26 2020-12-17 Ablynx N.V. Nucleotide sequences encoding peptide linkers
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
CN110396504A (zh) * 2018-04-25 2019-11-01 江苏省原子医学研究所 一种具有肿瘤靶向性的重组痘苗病毒及其制备方法、用途
CN114854720A (zh) 2018-06-30 2022-08-05 因思科瑞普特公司 用于改进活细胞中编辑序列的检测的仪器、模块和方法
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
EP3653716A1 (en) * 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
CA3134168A1 (en) 2019-03-25 2020-10-01 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
WO2020247587A1 (en) 2019-06-06 2020-12-10 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US11284783B2 (en) 2019-06-20 2022-03-29 Cilag Gmbh International Controlling integral energy of a laser pulse in a hyperspectral imaging system
EP4013788A1 (en) 2019-08-12 2022-06-22 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
KR102281858B1 (ko) * 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
WO2021102059A1 (en) 2019-11-19 2021-05-27 Inscripta, Inc. Methods for increasing observed editing in bacteria
CN114829607A (zh) 2019-12-18 2022-07-29 因思科瑞普特公司 用于体内检测核酸引导的核酸酶编辑的细胞的Cascade/dCas3互补测定
CA3157061A1 (en) 2020-01-27 2021-08-05 Christian SILTANEN Electroporation modules and instrumentation
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CN111944810B (zh) * 2020-07-29 2022-05-27 中国农业大学 靶向敲除TNFα基因的sgRNA和敲除TNFα基因的猪胚胎成纤维细胞系及其应用
US11299731B1 (en) 2020-09-15 2022-04-12 Inscripta, Inc. CRISPR editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
WO2022146497A1 (en) 2021-01-04 2022-07-07 Inscripta, Inc. Mad nucleases
WO2022150269A1 (en) 2021-01-07 2022-07-14 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA2018273C (en) 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5770428A (en) * 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
JPH08511156A (ja) 1993-04-06 1996-11-26 アメリカ合衆国 テナガザル白血球ウイルスベースのレトロウイルスベクター
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
EP0728195A1 (en) 1993-10-12 1996-08-28 Chiron Corporation Methods for preserving recombinant viruses
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
AU708972B2 (en) 1994-11-07 1999-08-19 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US20030157070A1 (en) 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
EP2017337A1 (en) 1995-04-27 2009-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
EP0961831B1 (en) 1996-08-16 2008-10-29 Human Genome Sciences, Inc. Human endokine alpha
AU4055697A (en) 1996-08-16 1998-03-06 Schering Corporation Mammalian cell surface antigens; related reagents
AU4503797A (en) 1996-09-27 1998-04-17 Maxygen, Inc. Methods for optimization of gene therapy by recursive sequence shuffling and selection
ATE302272T1 (de) 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
DE69834027D1 (de) 1997-01-14 2006-05-18 Human Genome Sciences Inc Tumor-nekrose-faktor rezeptor 5
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
IL130635A0 (en) 1997-01-17 2000-06-01 Maxygen Inc Evolution of whole cells and organisms by recursive sequence recombination
AU6250098A (en) 1997-01-28 1998-08-18 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
EP0996718B1 (en) 1997-03-18 2008-12-24 Novozymes A/S Method for constructing a library using dna shuffling
CN1249784A (zh) 1997-03-18 2000-04-05 诺沃挪第克公司 一种体外构建dna文库的方法
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
JP2002511070A (ja) 1997-05-30 2002-04-09 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒト腫瘍壊死因子受容体ｔｒ１０
WO1998056892A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
WO1999020742A2 (en) 1997-10-20 1999-04-29 Universita' Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
WO1999023107A1 (en) 1997-10-31 1999-05-14 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
AU746786B2 (en) 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
JP2002503478A (ja) 1998-02-11 2002-02-05 マキシジェン， インコーポレイテッド 遺伝子ワクチンベクターの標的化
JP2002507393A (ja) 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド 抗原ライブラリー免疫
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
JP2002512805A (ja) 1998-04-29 2002-05-08 オクラホマ メディカル リサーチ ファウンデーション アデノウイルスベクターおよびレトロウイルスベクターからのレトロウイルスプロデューサー細胞の構築
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
GB9810752D0 (en) 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
AU4089899A (en) 1998-05-20 1999-12-06 University Of Tennessee Research Corporation, The Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
JP4700805B2 (ja) 1998-06-29 2011-06-15 ブリストル−マイヤーズ スクウィブ カンパニー 多様性の高いライブラリーを製造する方法
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
FR2782323B1 (fr) 1998-08-12 2002-01-11 Proteus Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues
CA2331335A1 (en) 1998-09-29 2000-04-06 Maxygen, Inc. Shuffling of codon altered genes
US6899871B2 (en) 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
DE69940521D1 (de) * 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
EP1151409A1 (en) 1999-01-18 2001-11-07 Maxygen, Inc. Methods of populating data stuctures for use in evolutionary simulations
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
DK1072010T3 (da) 1999-01-19 2010-06-21 Maxygen Inc Oligonukleotidmedieret nukleinsyrerekombination
AU4559800A (en) 1999-04-29 2000-11-17 Aarhus Universitet Expression of heterologous genes from an ires translational cassette in retroviral vectors
AU6085500A (en) 1999-07-08 2001-01-30 Regents Of The University Of California, The A lung cancer associated retrovirus, gene delivery vector and methods of use thereof
WO2001040488A1 (en) 1999-11-30 2001-06-07 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
AU2001241939A1 (en) 2000-02-28 2001-09-12 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US20020137889A1 (en) 2000-09-18 2002-09-26 Soong Nay Wei Stress resistant retroviruses
WO2002042482A2 (en) * 2000-11-27 2002-05-30 Chiron Corporation Functional lentiviral vector from an mlv-based backbone
WO2002061104A2 (en) 2001-01-30 2002-08-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hybrid adenoviral vector
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
AU2002326907B2 (en) * 2001-09-13 2008-04-03 California Institute Of Technology Method for expression of small RNA molecules within a cell
FR2832424B1 (fr) 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
WO2003064666A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US20040068762A1 (en) 2002-07-17 2004-04-08 Attar Ricardo M. Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements
WO2004022761A1 (en) * 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
US7790445B2 (en) * 2003-07-21 2010-09-07 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
US20080227736A1 (en) 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
US20070003522A1 (en) 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
MX2007003804A (es) 2004-11-04 2007-04-23 Pfizer Prod Inc Tratamiento combinado de anticuerpo anti-ctla4 e inhibidor de aromatasa para el cancer de mama.
WO2006058231A2 (en) * 2004-11-24 2006-06-01 Nanovector Limited Viral vectors
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
US7968698B2 (en) 2005-05-25 2011-06-28 The Regents Of The University Of California Optimized core promoters and uses thereof
US20070048285A1 (en) * 2005-08-24 2007-03-01 Christopher Baum Self-inactivating retroviral vector
WO2007036233A2 (en) * 2005-09-30 2007-04-05 Zgene A/S Dekkera/brettanomyces cytosine deaminases and their use
JP5976986B2 (ja) * 2005-10-01 2016-08-24 チャールズ スタウト， 調節可能な融合プロモーター
WO2007044483A2 (en) 2005-10-07 2007-04-19 President And Fellows Of Harvard College Attenuated vaccines for non-segmented negative sense rna viruses
EP1795596A1 (en) * 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
EP2487253B1 (en) * 2006-01-05 2015-06-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007095201A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
WO2007107156A2 (en) 2006-03-17 2007-09-27 Aarhus Universitet Chimeric viral envelopes
AU2007241023B2 (en) * 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
KR101421312B1 (ko) * 2006-07-21 2014-07-31 캘리포니아 인스티튜트 오브 테크놀로지 수지상 세포 백신접종을 위한 표적화된 유전자의 전달
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
MX366570B (es) * 2008-06-30 2019-07-12 Tocagen Inc Formulaciones de 5-fluorocitosina y usos de las mismas.
ES2709481T3 (es) * 2008-09-26 2019-04-16 Tocagen Inc Vectores recombinantes
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
EP3159415B1 (en) * 2009-06-17 2019-03-13 Tocagen Inc. Producer cells for replication competent retroviral vectors
CA2805803A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (hppd) activity

Also Published As

Publication number Publication date
CN102227501B (zh) 2016-11-16
EP3460061A1 (en) 2019-03-27
CN102227503B (zh) 2015-10-21
DK2346995T3 (en) 2019-02-11
JP2012503986A (ja) 2012-02-16
CN105274125A (zh) 2016-01-27
MX2011003039A (es) 2011-08-15
CN102227503A (zh) 2011-10-26
NZ592070A (en) 2012-07-27
JP2015119712A (ja) 2015-07-02
KR20180069131A (ko) 2018-06-22
MX2018008440A (es) 2021-06-15
US20140242033A1 (en) 2014-08-28
IL248833B (en) 2019-01-31
US10035983B2 (en) 2018-07-31
WO2010045002A2 (en) 2010-04-22
BRPI0919113A2 (pt) 2016-08-09
US20190185821A1 (en) 2019-06-20
US8722867B2 (en) 2014-05-13
CO6362050A2 (es) 2012-01-20
MY156333A (en) 2016-02-15
JP6523224B2 (ja) 2019-05-29
EP2344648A4 (en) 2012-03-14
EP2346995B1 (en) 2018-11-07
MX357418B (es) 2018-07-09
KR20160079149A (ko) 2016-07-05
JP5771147B2 (ja) 2015-08-26
ES2706899T3 (es) 2019-04-01
CA2738472A1 (en) 2010-04-22
KR101724162B1 (ko) 2017-04-07
JP2019141088A (ja) 2019-08-29
CN105624193A (zh) 2016-06-01
EP2346995A2 (en) 2011-07-27
AU2009303690B2 (en) 2014-06-19
AU2009303690A1 (en) 2010-04-22
KR102025502B1 (ko) 2019-09-25
CN102227501A (zh) 2011-10-26
US20110217267A1 (en) 2011-09-08
EP2344648B1 (en) 2018-11-14
CN105624193B (zh) 2021-07-13
EA201170492A1 (ru) 2011-10-31
JP2017018121A (ja) 2017-01-26
ZA201102115B (en) 2012-07-25
EP3502256A3 (en) 2019-09-25
JP5992548B2 (ja) 2016-09-14
EP3502256A2 (en) 2019-06-26
IL264214A (en) 2019-02-28
IL211847A0 (en) 2011-06-30
JP5684130B2 (ja) 2015-03-11
JP2015186479A (ja) 2015-10-29
WO2010045002A3 (en) 2010-08-26
WO2010036986A3 (en) 2010-07-01
KR20110063673A (ko) 2011-06-13
JP6062485B2 (ja) 2017-01-18
IL248833A0 (en) 2017-01-31
IL211847A (en) 2016-11-30
KR101870056B1 (ko) 2018-07-23
EA027693B1 (ru) 2017-08-31
IL264214B (en) 2020-01-30
WO2010036986A2 (en) 2010-04-01
EA201790824A2 (ru) 2017-08-31
JP2012503987A (ja) 2012-02-16
EP2346995A4 (en) 2011-12-07
EP2344648A2 (en) 2011-07-20
ES2709481T3 (es) 2019-04-16

Similar Documents

Publication Publication Date Title
EA201170492A1 (ru) Векторы для генной терапии и цитозиндезаминазы
NL301145I2 (nl) Tirbanibulin
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
WO2011126864A3 (en) Cancer treatment with recombinant vector
MX2009012623A (es) Moduladores de cinasa heterociclicos.
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
MX2018011791A (es) Compuestos para transduccion viral mejorada.
WO2006125640A3 (en) Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
EA200800229A1 (ru) Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1)
TW200732347A (en) VEGF analogs and methods of use
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2007042309A3 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
NO20081084L (no) Arylpyridiner og fremgangsmater for deres anvendelse
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
WO2007065010A3 (en) Anti-angiogenesis compounds
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
IL184734A0 (en) Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
EA200901621A1 (ru) Индукция толерогенного фенотипа у зрелых дендритных клеток
NZ708349A (en) Egfr and c-met fibronectin type iii domain binding molecules
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης